• Safety, in terms of absences of severe adverse events (SAE) and unacceptable toxicity [ Designated as safety issue: Yes ]
  
• Tumor response, according to RECIST criteria [ Designated as safety issue: No ]
  

OBJECTIVES:

• Document radiologic and/or tumor marker response to cryotherapy of tumor lesions followed by cyclophosphamide.

OUTLINE: This is a pilot study.

Patients undergo percutaneous biopsy of the targeted lesion prior to cryoablation. Patients then undergo percutaneous or open cryotherapy of the largest or most accessible lesion on day 0. On day 3, patients receive cyclophosphamide IV over 1 hour.

Tumor markers (if applicable) are assessed at baseline and monthly during study until marker progression.

After completion of study therapy, patients are followed periodically for up to 3 years.

DISEASE CHARACTERISTICS:

• Diagnosis of epithelial solid tumors of any of the following sites or types:

  • Lung
  • Renal
  • Prostate
  • Breast
  • Sarcoma
  • Colon
  • Liver
  • Pancreatic
  • Bone
  • Head and neck
  • Melanoma
  • Carcinoma of unknown primary
• Advanced or metastatic disease
• Ineligible for or unwilling to undergo surgical resection
• Eligible for cryotherapy but not expected to be cured by cryotherapy alone

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Life expectancy > 3 months
• Creatinine < 2.5 mg/dL
• Platelet count >75,000/mm³
• INR< 1.5
• No known HIV positivity
• No active, uncontrolled infection
• Not pregnant
• Negative pregnancy test
• Women of childbearing potential must practice adequate contraception
• No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics